Protein Degradation Therapy Market Report 2026

Protein Degradation Therapy Market Overview

• Protein Degradation Therapy market size has reached to $1.25 billion in 2025 • Expected to grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 7.8% • Growth Driver: Rising Cancer Burden Drives Growth In Protein Degradation Therapy Market • Market Trend: Strategic Partnerships Drive Innovation In Protein Degradation Therapy Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Protein Degradation Therapy Market?

Protein degradation therapy is a therapeutic approach that targets the selective degradation of specific proteins within cells. This method involves using small molecules, peptides, or other agents to induce the destruction of proteins that are dysfunctional or contribute to disease. The goal is to reduce or eliminate harmful proteins that are associated with various conditions, such as cancer, neurodegenerative diseases, and autoimmune disorders. The main protein degradation therapy includes bavdegalutamide (ARV-110), vepdegestrant (ARV-471), and others. Bavdegalutamide, also known as ARV-110, is a novel therapy designed to target and degrade androgen receptors in prostate cancer cells. It is applied for oncology, neurodegenerative diseases, infectious diseases, and others by various end-users such as pharmaceutical companies, biotechnology companies, and academic and research institutes.

What Is The Protein Degradation Therapy Market Growth Forecast?

The protein degradation therapy market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing demand for novel cancer therapies, rising investments in precision oncology, expansion of protein degradation platforms, growing clinical trial activity, increasing regulatory support for innovative therapeutics. Major trends in the forecast period include increasing development of targeted protein degraders, rising focus on oncology applications, growing investment in protac-based therapies, expansion of clinical pipeline candidates, enhanced collaboration between pharma and biotech firms.

Global Protein Degradation Therapy Market Segmentation

1) By Type: Bavdegalutamide (ARV - 110), Vepdegestrant (ARV - 471) 2) By Application: Oncology, Neurodegenerative Diseases, Infectious Diseases, Other Applications 3) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes Subsegments: 1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders, Prostate Cancer Therapy 2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders, Breast Cancer Therapy

What Is The Driver Of The Protein Degradation Therapy Market?

The growing burden of cancer is expected to propel the growth of the protein degradation therapy market going forward. Cancer comprises a range of diseases marked by the uncontrolled proliferation and dissemination of abnormal cells within the body. Cancer rates are rising primarily due to a combination of factors, with the aging population being a significant contributor. Additionally, lifestyle factors such as smoking, poor diet, lack of physical activity, and rising obesity rates have increased the risk of various cancers. Protein degradation therapy is required for treating cancer because it targets and eliminates specific proteins that drive cancer growth and survival, potentially overcoming resistance to traditional treatments. For instance, in February 2024, according to a report published by the World Health Organization, a Switzerland-based intergovernmental organization, over 35 million new cancer cases are anticipated in 2050, representing a 77% increase from the estimated 20 million cases in 2022. Moreover, high human development index (HDI) countries are projected to see the largest increase in absolute numbers, with an additional 4.8 million new cases predicted in 2050 compared with 2022 estimates. Therefore, the growing burden of cancer is driving the growth of the protein degradation therapy industry.

Key Players In The Global Protein Degradation Therapy Market

Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc

Global Protein Degradation Therapy Market Trends and Insights

Major companies operating in the protein degradation therapy market are adopting a strategic partnership approach to develop innovative therapies, leverage complementary expertise, share resources, and accelerate the discovery and development of new drug candidates targeting disease-causing proteins. Strategic partnerships involve companies utilizing each other's strengths and resources to gain mutual benefits and achieve shared success. For instance, in February 2024, Arvinas, a U.S.-based biotechnology company, introduced its first oral PROTAC degrader (ARV-102), which is designed to cross the blood-brain barrier and target LRRK2 for neurodegenerative disease applications. The ARV-102 molecule features oral bioavailability, a brain-penetrant profile, and high specificity for LRRK2. This innovation strengthens companies’ pipelines by addressing previously undruggable targets, though challenges remain around long-term safety, manufacturing complexity, and optimization of pharmacokinetics given the larger molecular structure.

What Are Latest Mergers And Acquisitions In The Protein Degradation Therapy Market?

In June 2024, Genexine, a South Korea-based biopharmaceutical company, merged with EPD Biotherapeutics for an undisclosed amount. As a result of the merger, Genexine has secured key talent and cutting-edge technology that positions it to lead the global market. Additionally, integrating EPD Bio’s bioPROTAC technology with Genexine’s clinical and CMC development capabilities will advance the development of groundbreaking new drugs. EPD Biotherapeutics is a South Korea-based developer of protein degradation platform called EPDeg.

Regional Insights

North America was the largest region in the protein degradation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Protein Degradation Therapy Market?

The protein degradation therapy market consists of revenues earned by entities by providing services such as drug discovery and development, target validation, preclinical and clinical testing and targeted protein degradation screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The protein degradation therapy market also includes sales of degraders, E3 ligase ligands, degron tags, biochemical assay kits and cellular assay kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Protein Degradation Therapy Market Report 2026?

The protein degradation therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the protein degradation therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.